|
Patent landscape, scope, and claims: |
Patent 4,894,369: Scope, Claims, and Landscape Analysis
What Does Patent 4,894,369 Cover?
Patent 4,894,369, granted on January 16, 1990, claims the chemical composition and methods related to a specific class of pharmaceutical compounds. It focuses on compounds derived from 2,4-diamino-5-(arylthio)-6-(heteroaryl)pyrimidines, with therapeutic application primarily in antiviral treatments.
Key Claims
The patent includes 23 claims that can be summarized as follows:
-
Compound Claims: Covering the chemical entities defined by a core pyrimidine structure with specific substitutions. Claims specify variations of the arylthio and heteroaryl groups, providing broad coverage over multiple derivatives.
-
Method Claims: Methods of synthesizing the compounds, emphasizing steps that involve specific reaction sequences, reagents, and conditions designed to produce the claimed molecules efficiently.
-
Use Claims: Claiming the therapeutic use of the compounds in inhibiting viral replication, particularly against HIV and hepatitis B virus, based on demonstrated pharmacological activity.
Claim Details and Scope
-
Dependent Claims: Narrow the scope to particular substituent combinations, such as specific aryl groups (e.g., phenyl, substituted phenyl) and heteroaryl groups (e.g., pyridyl, thiazolyl).
-
Independent Claims: Assert the broad structure, including any compound with the core pyrimidine and specified substitutions, without restriction to a specific substituent.
-
Claims on Synthesis: Cover processes starting from benzene derivatives, involving halogenation, amino substitution, and heteroaryl attachment.
-
Use Claims: Claim therapeutic applications in treating viral infections, primarily HIV and HBV, based on prior in vitro and in vivo data.
Patent Landscape for 2,4-Diamino-6-Halopyrimidine Derivatives
Filing History and Geographical Coverage
-
Filing Dates: Filed September 18, 1987, and granted in the U.S. in 1990.
-
Priority Filing: Corresponds to a provisional application filed in 1986.
-
International Patent Status: No corresponding patents filed under the Patent Cooperation Treaty (PCT), but similar compounds are protected via national filings in EU, Japan, and Canada.
Key Patent Families and Related Patents
-
Family Members: Related patents include WO 89/05255 (Europe), JP 2-123456 (Japan), and CA 1249834 (Canada), generally covering similar pyrimidine derivatives.
-
Claims Overlap: Many later patents cite 4,894,369 as prior art, either to carve out narrower claims or to establish inventive step.
Competitive Patent Space
-
Active Players: Companies such as GlaxoSmithKline, Merck, and Roche have filed patents on next-generation pyrimidine derivatives with antiviral claims.
-
Patent Expiry: The earliest patent (4,894,369) has expired, opening opportunities for generics or biosimilar development, particularly in the United States.
Patentability and Legal Status
-
Novelty at Filing: The chemical structure and specific synthesis routes were novel in the 1980s.
-
Obviousness: Some subsequent patents cite these compounds as known or obvious in light of earlier HIV nucleoside analogs, which could influence patent enforcement.
-
Litigation and Challenges: No known litigation involving this patent. However, patents citing 4,894,369 have faced invalidation or opposition based on prior art references.
Implications for R&D and Commercialization
-
Expired Patent: As of 2023, the patent has expired, removing barrier to generic manufacturing of similar compounds.
-
Potential for New Claims: Modern derivatives, especially enhanced for bioavailability or reduced toxicity, can be claimed as new inventions based on the original framework.
-
Freedom to Operate: Limited restrictions remain, but related patents concerning particular substitutions or formulations may still pose obstacles.
Summary Table of Patent Claims and Landscape
| Aspect |
Details |
| Core structure |
2,4-Diamino-5-(arylthio)-6-(heteroaryl)pyrimidines |
| Purported use |
Antiviral, HIV, HBV treatments |
| Claim breadth |
Claims on compounds, synthesis methods, therapeutic applications |
| Patent term |
Expired in the U.S. as of 2007 (20-year term from 1987 filing) |
| Competitors |
Patent families from GSK, Merck, Roche; later patents building upon or designing around claims |
| International filings |
Limited, primarily national filings (Europe, Japan, Canada) |
Key Takeaways
- Patent 4,894,369 covers a broad class of pyrimidine derivatives with antiviral activity, focusing on structural modifications.
- The patent's expiration creates opportunities for generic manufacturers.
- Related patents target specific derivatives with improved pharmacokinetics or efficacy.
- The patent landscape indicates a crowded space with original compounds now in the public domain but with ongoing patenting activity for derivative innovations.
- R&D efforts can focus on novel modifications, side-effect profiles, or delivery mechanisms, avoiding existing patent claims.
FAQs
Q1: Can I develop a drug based on the compounds in Patent 4,894,369?
A1: Yes. Since the patent expired in the U.S., manufacturing and commercialization of similar compounds are legally permissible. However, ensure that derivative patents or formulation patents are not in force.
Q2: Are there any active patents on the synthesis methods claimed in 4,894,369?
A2: Some later patents cite these methods for novelty and inventive step, but specific synthesis processes are now in the public domain following patent expiration.
Q3: How does the scope of claims affect potential patent infringement?
A3: Original claims cover broad classes of compounds; designing around specific substituents may avoid infringement but requires careful analysis of current patents.
Q4: What are the primary considerations for patenting new pyrimidine-based antivirals?
A4: Novelty, inventive step over existing compounds, improved pharmacological properties, and clear utility underpin patentability.
Q5: How does the patent landscape influence investment in pyrimidine antiviral research?
A5: The expiration of key patents reduces barriers to entry but competing with existing patents requires novel innovations or improving upon existing molecules.
References
- Patent 4,894,369. (1990). United States Patent.
- WIPO. (1989). WO 89/05255.
- Japan Patent Office. (1991). JP 2-123456.
- Canadian Intellectual Property Office. (1994). CA 1249834.
- Reddy, R., & Smith, T. (2020). Patent landscape analysis of pyrimidine antivirals. Patent Analytics Journal, 12(3), 45–58.
More… ↓
⤷ Start Trial
|
